Sorafenib in metastatic thyroid cancer: a systematic review.

ABSTRACT:

Background

Sorafenib was recently approved by the U.S. Food and Drug Administration for radioiodine-resistant metastatic differentiated thyroid cancer (DTC). In addition, two drugs (vandetanib and cabozantinib) have received U.S. Food and Drug Administration approval for use in medullary thyroid cancer (MTC). Several published phase II trials have investigated the efficacy of sorafenib in thyroid cancers, but to date, results from those studies have not been compared.

Methods

A systematic review of the literature was performed to assess response rate, median progression-free survival, and adverse events associated with sorafenib therapy for metastatic thyroid cancers.

Results

This review included seven trials involving 219 patients: 159 with DTC (papillary, follicular

SUBMITTER: Thomas L 

PROVIDER: S-EPMC3958462 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature